Suzhou Basecare Medical (HKSE:02170) LT-Debt-to-Total-Asset : 0.16 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Suzhou Basecare Medical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Suzhou Basecare Medical's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.16.

Suzhou Basecare Medical's long-term debt to total assets ratio increased from Jun. 2023 (0.11) to Jun. 2024 (0.16). It may suggest that Suzhou Basecare Medical is progressively becoming more dependent on debt to grow their business.

Suzhou Basecare Medical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Suzhou Basecare Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Basecare Medical LT-Debt-to-Total-Asset Chart

Suzhou Basecare Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.04

0.14

Suzhou Basecare Medical Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial						0.03	0.04	0.11	0.14	0.16

Suzhou Basecare Medical LT-Debt-to-Total-Asset Calculation

Suzhou Basecare Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	291.745	/	2076.087
	=	0.14

Suzhou Basecare Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	312.682	/	1935.341
	=	0.16

Suzhou Basecare Medical (HKSE:02170) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Suzhou Basecare Medical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Suzhou Basecare Medical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Basecare Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Suzhou Basecare Medical Corp Ltd (HKSE:02170) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

BioBay, No. 218 Xinghu Street, Unit 101, Building A3, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000

Website

https://www.basecare.cn

Suzhou Basecare Medical Corp Ltd is engaged in providing genetic testing solutions for assisted human reproduction. The company generates revenues from Sales of testing kits, followed by Sales of testing devices, instruments, and consumables. Basecare focuses on the assisted reproductive sector, such as pre-implantation genetic screening and diagnosis, non-invasive prenatal DNA testing, and chromosome abnormalities testing. Geographically the company generates the majority of its revenue from the PRC.

Executives

Orbimed Capital Llc	2102 Investment manager
Lake Bleu Prime Healthcare Master Fund Limited	2201 Interest of corporation controlled by you
Orbimed Partners Master Fund Limited	2101 Beneficial owner
Dawn Capital Fund	2101 Beneficial owner
Dawn Capital Limited	2102 Investment manager
Hh Spr-xiv Cy Holdings Limited	2201 Interest of corporation controlled by you
Hh Spr-xiv Hk Holdings Limited	2101 Beneficial owner
Hh Spr-xiv Holdings L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager

Suzhou Basecare Medical Headlines

No Headlines